Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

NCT00999882 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Advanced Hepatocellular Carcinoma

Interventions

DRUG: AZD8055

Sponsor

AstraZeneca